Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

Results 1 - 9 of 9

Recs

0
Member Avatar pchop12316 (37.84) Submitted: 1/29/2015 11:26:18 AM : Outperform Start Price: $3.31 GALT Score: -2.67

Upside may be imminent

Recs

3
Member Avatar zzlangerhans (99.85) Submitted: 1/19/2015 10:43:08 PM : Outperform Start Price: $3.33 GALT Score: -2.38

As I predicted, Galectin filled the gap after spiking on a meaningless PR of completion of the phase I trial. I expect Galectin to settle into a narrow range again as the company prepares for phase II trials of GR-MD-02 for NASH. If I go long Galectin again, I expect to do so very gradually as there's a lot of time for the stock to decay before a significant positive catalyst becomes visible on the horizon.

Recs

0
Member Avatar spirts (< 20) Submitted: 12/24/2014 6:40:07 AM : Outperform Start Price: $3.04 GALT Score: +10.04

GALT

Recs

0
Member Avatar Allstar13913 (99.83) Submitted: 9/11/2014 10:09:44 PM : Underperform Start Price: $5.59 GALT Score: +42.07

Stock Promoter Pump and dump that uses Redchip.com to fool retail investors into buying. The company was formerly bankrupt and is a con job. Don't buy.

Recs

0
Member Avatar superstar (99.60) Submitted: 7/30/2014 11:21:17 AM : Outperform Start Price: $7.15 GALT Score: -55.93

I liked the GALT statement issued on its GR-MD-02 Development Program. The company believes the market misinterpreted positive clinical data.

Recs

0
Member Avatar newt1322 (< 20) Submitted: 9/16/2013 11:54:30 AM : Outperform Start Price: $10.35 GALT Score: -85.59

galt is 20 years ahead of everyone else due to the smart move of bringing the lead russian scientist over and securing his 20-25 years of research and folding it into what they knew about the molecules.

Recs

0
Member Avatar adi101 (92.06) Submitted: 8/4/2013 1:42:20 PM : Outperform Start Price: $6.00 GALT Score: -63.26



Specilative

Recs

3
Member Avatar BuffettJunior1 (97.73) Submitted: 6/2/2011 4:58:08 PM : Underperform Start Price: $7.74 GALT Score: +111.64

The only thing this company is good at is burning money. Over the past 10 years the company hasn't made a dime. I still don't understand how this garbage stock has a market cap of 100 million.

Recs

0
Member Avatar Biotoday (44.46) Submitted: 10/7/2010 11:26:17 AM : Outperform Start Price: $4.33 GALT Score: -97.57

From Accredited Investor grapevine

Results 1 - 9 of 9

Featured Broker Partners


Advertisement